The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


Second Trial of New Eczema Drug To Commence in Q4/22

Research Report
  ()
The purpose behind this complementary study is to potentially expand the treatment's target patient population, noted an H.C. Wainwright & Co. report.

Price Target on US Biopharma Co. Boosted by $15

Research Report
  ()
The increase came after positive clinical trial results on one of its lead drug candidates differentiating it from a competitor, noted a BTIG report.

New Drug Shown To Help Patients With Desmoid Tumors

Research Report
  ()
This oral gamma-secretase inhibitor met the primary and secondary endpoints in a Phase 3 clinical trial, noted a Wedbush report.

NDA for Dry Eye Disease Drug on Track for Q4/22 Submission

Research Report
  ()
This and the biopharma's other treatment candidates for ocular diseases are underappreciated, which translates to an investment opportunity, noted an Oppenheimer report.

Co. Advancing Drug Class With Broad Potential

Research Report
  ()
This developer of C1q-targeting therapeutics, with a catalyst-rich 18 months ahead, warrants analyst coverage, noted a BTIG report.

Expert Says Life Science Co.'s Technical Setup Is 'Exceptionally Positive and Keeps Getting Better'

Contributed Opinion
  ()
Expert Clive Maund reviews the 6-month and 15-month charts for Awakn Life Sciences Corp. to explain why he thinks this company's technical setup is exceptionally positive.

Healthcare Co.'s To Develop Fast-Dissolving MDMA Tablet

  ()
One biopharma co. is teaming with a much larger pharmaceutical company to develop a fast-dissolving oral tablet to deliver MDMA to patients with Alcohol Use Disorder. Find out why developing an oral tablet could benefit the company in the long run.

Analyst Says Biopharma's New Inhaled Antifungal Drug Shows Promise

Research Report
  ()
Trial results are expected later this month, but anecdotal data available now suggest the findings should be positive, noted a ROTH Capital Partners report.

US Co. To Regain All Rights to Its AGHD Diagnostic Test

Research Report
  ()
This is set to happen because the biopharma's commercialization partner recently terminated its agreement over the product, noted an H.C. Wainwright & Co. report.

Biopharma Co. Transforming Injected Drugs Into Pills

Research Report
  ()
This Israeli firm recently attracted the attention of the US-based financial institution, H.C. Wainwright & Co., which launched analyst coverage of it.

Expert Says Life Science Corp.'s Technical Case Is Becoming Compelling

Contributed Opinion
  ()
Expert Clive Maund shares his view on Awakn Life Sciences Corp. as its stock continues to strengthen.

Two Talks On New Cancer Drug Slated for Meeting This Week

Research Report
  ()
The upcoming discussions pertain to a biopharma's clinical stage T-cell therapy as a treatment for solid tumors, noted a ROTH Capital Partners report.

Will Pharma Co. Keep Pushing Higher After Full Data Set Released on Lung Disease Study?

  ()
One small-cap pharma co. just published more good news on a possible treatment for patients suffering from idiopathic pulmonary fibrosis, a lung disease that's usually terminal. Find out why the company has more near-term catalysts and may continue to build on an 84% gain since a private placement in mid-August.

Expert Rates Pharma Co. An Immediate Buy

Contributed Opinion
  ()
Expert Chris Temple gives his view on Algernon Pharmaceuticals stock in light of its positive results for its Phase 2a study for the treatment of idiopathic pulmonary fibrosis and chronic cough.

FDA OKs Biopharma to Trial New Cell Therapy

Research Report
  ()
Now with clearance, the firm plans to commence a Phase 1 study of its lead candidate in patients with lymphoma by the end of this year, noted an H.C. Wainwright & Co. report.

Delay in New Drug Filing Now Could Yield Benefits Later

Research Report
  ()
The developer of genetic medicines is taking six more months to conduct longer preclinical safety studies involving its lead therapeutic, noted an Oppenheimer report.

ACC Recommends Approved Drug for Lowering LDL

Research Report
  ()
This same medicine is currently being evaluated in a global clinical trial from which topline results are expected in Q1/23, noted an H.C. Wainwright & Co. report.

Biotech Co. Signs Option Agreement With Drug Co. to Find Ideal Ketamine Formula

  ()
A small biotech has taken further steps to deepen the intellectual property moat for its potentially revolutionary treatment for alcohol addiction. Find out which company it is and why one analyst has given it a CA$8 target price.

First Data Due by Year End 2022 From Study of New HAE Drug

Research Report
  ()
Management's ongoing execution is raising the biopharma's profile among investors, noted an Oppenheimer report.

Showing Results: 51 to 75 of 151 Prev Next

Get Our Streetwise Reports Resources Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts